Pharmala Biotech (MDMA) Q1 2025 earnings summary

Executive summary

• Revenue exceeded CAD 1 million in fiscal 2024, up 95% year-over-year, but quarterly revenue dropped to $57,297 from $752,470 last year due to shipment and distribution delays.

• Net loss for the quarter was $479,109, compared to a net profit of $36,477 in the prior year, driven by lower sales and higher stock-based compensation.

• Distribution was disrupted by the termination of a supply agreement but resumed with a new partner, Rane Pharmaceuticals, after November 30, 2024.

• The company is actively seeking a U.S.-based distributor to streamline operations and reduce cross-border risks.

• Completed a $1.56 million private placement after quarter-end to support patent rights, manufacturing, and clinical trials.

Financial highlights

• MDMA product sales reached CAD 723,000, a 73% increase year-over-year, but no product revenue was recognized in the quarter due to shipment delays.

• Customer deposits rose to CAD 283,000 in Q1, up from CAD 208,000 at fiscal year-end.

• Revenue recognition is tied to product delivery, with deposits generally representing up to 50% of contract value.

• Cash at quarter-end was $198,549, down from $419,379 at the start of the quarter.

• Operating expenses increased, notably stock-based compensation ($226,295 vs. $18,780) and professional fees ($50,614 vs. $7,797).

Outlook and guidance

• Management expects revenue to recover as new distribution partnerships and export permits enable product shipments.

• Proceeds from the recent private placement will fund IP, manufacturing, clinical trials, and working capital.

• Expects to announce progress on non-dilutive funding for Phase 2 trials and preclinical development within the next quarter, though timelines may shift.

• U.S. market seen as a key growth area, with increased government funding and clinical trial activity.

• The company continues to monitor economic and regulatory trends affecting the psychedelics sector.